Pregnant women with hepatitis c get new hope from 12-Week drug trial

NCT ID NCT05140941

Ongoing Disease control Sponsor: Catherine Anne Chappell Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a 12-week course of the drug Sofosbuvir/Velpatasvir in about 100 pregnant women with chronic hepatitis C. The goal is to see if the treatment can cure the virus and whether it affects the timing of delivery. Mothers are followed for 12 weeks after treatment, and babies are monitored for one year to check safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection hepatitis C virus infection Pregnancy Complications, Infectious

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C, CHRONIC PREGNANCY; INFECTION

Contacts and locations

Locations

Marshall University

Huntington, West Virginia, 25755, United States
The Christ Hospital

Cincinnati, Ohio, 45219, United States
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
Toronto General Hospital, University Health Network

Toronto, Ontario, M5G 2C4, Canada
University Health Toronto, St Michaels Hospital

Toronto, Ontario, M5B 1W8, Canada
University of Pittsburgh, Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213, United States
University of Utah

Salt Lake City, Utah, 84132, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Victoria Hospital, London Health Sciences Center

London, Ontario, N6A 5W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.